NCT03200717 - Study of Efficacy, Safety, and Quality of Life of Pazopanib in Patients With Advanced and/or Metastatic Renal Cell Carcinoma After Prior Checkpoint Inhibitor Treatment | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

November 14, 2017

Primary Completion Date

August 10, 2021

Study Completion Date

August 10, 2021

Conditions

Advanced Renal Cell CarcinomaMetastatic Renal Cell Carcinoma

Interventions

DRUG

Pazopanib

Participants received 800mg of pazopanib once daily orally. Pazopanib was supplied as aqueous film-coated tablets containing 200 mg or 400 mg.

Trial Locations (22)

5020

Novartis Investigative Site, Salzburg

8036

Novartis Investigative Site, Graz

14263

Roswell Park Cancer Institute, Buffalo

28041

Novartis Investigative Site, Madrid

30625

Novartis Investigative Site, Hanover

41013

Novartis Investigative Site, Seville

59300

Novartis Investigative Site, Valenciennes

72076

Novartis Investigative Site, Tübingen

75015

Novartis Investigative Site, Paris

4810469

Novartis Investigative Site, Temuco

8420383

Novartis Investigative Site, Santiago

C1280AEB

Novartis Investigative Site, Caba

A-1090

Novartis Investigative Site, Vienna

T2N 4N2

Novartis Investigative Site, Calgary

656 53

Novartis Investigative Site, Brno

775 20

Novartis Investigative Site, Olomouc

F 67098

Novartis Investigative Site, Strasbourg

07740

Novartis Investigative Site, Jena

H 1122

Novartis Investigative Site, Budapest

NW3 2QG

Novartis Investigative Site, London

M20 2BX

Novartis Investigative Site, Manchester

PR2 9HT

Novartis Investigative Site, Preston